HQSAR Study on Substituted 1H-Pyrazolo[3,4-b]pyridines Derivatives as FGFR Kinase Antagonists |
Bhujbal, Swapnil P.
(Department of Biomedical Sciences, College of Medicine, Chosun University)
Balasubramanian, Pavithra K. (Department of Biomedical Sciences, College of Medicine, Chosun University) Keretsu, Seketoulie (Department of Biomedical Sciences, College of Medicine, Chosun University) Cho, Seung Joo (Department of Biomedical Sciences, College of Medicine, Chosun University) |
1 | J. M. Siegfried, M. Farooqui, N. J. Rothenberger, S. Dacic, and L. P. Stabile, "Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer", Oncotarget, Vol. 8, pp. 24063-24076, 2017. |
2 | E. M. Haugsten, A. Wiedlocha, S. Olsnes, and J. Wesche, "Roles of fibroblast growth factor receptors in carcinogenesis", Mol. Cancer Res., Vol. 8, pp. 1439-1452, 2010. DOI |
3 | Y. J. Shi, J. Y. Tsang, Y. B. Ni, S. K. Chan, K. F. Chan and G. M. Tse, "FGFR1 is an adverse outcome indicator for luminal A breast cancers", Oncotarget, Vol. 7, pp. 5063-5073, 2016. DOI |
4 | N. Turner and R. Grose, "Fibroblast growth factor signalling: from development to cancer", Nat. Rev. Cancer, Vol. 10, pp. 116-129, 2010. DOI |
5 | N. Brooks, E. Kilgour, and P. D. Smith, "Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer", Clin. Cancer Res., Vol. 18, pp. 1855-1862, 2012. DOI |
6 | S. Lemieux and M. K. Hadden, "Targeting the fibroblast growth factor receptors for the treatment of cancer", Anti-Cancer Agents Med. Chem., Vol. 13, pp. 748-761, 2013. DOI |
7 | R. Porta, R. Borea, A. Coelho, S. Khan, A. Araujo, P. Reclusa, T. Franchina, N. V. D. Steen, P. V. Dam, J. Ferri, R. Sirera, A. Naing, D. Hong, and C. Rolfo, "FGFR a promising druggable target in cancer: Molecular biology and new drugs", Crit. Rev. Oncol. Hematol., Vol. 113, pp. 256-267, 2017. DOI |
8 | H. Izzedine, S. Ederhy, F. Goldwasser, J. C. Soria, G. Milano, A. Cohen, D. Khayat, and J. P. Spano, "Management of hypertension in angiogenesis inhibitor-treated patients", Ann. Oncol., Vol. 20, pp. 807-815, 2009. DOI |
9 | S. Ricciardi, S. Tomao, and F. de Marinis, "Toxicity of targeted therapy in non-small-cell lung cancer management", Clin. Lung Cancer, Vol. 10, pp. 28-35, 2009. DOI |
10 | B. Zhao, Y. Li, P. Xu, Y. Dai, C. Luo, Y. Sun, J. Ai, M. Geng, and W. Duan, "Discovery of substituted 1H-Pyrazolo[3,4-b]pyridine derivatives as potent and selective FGFR kinase inhibitors", ACS Med. Chem. Lett., Vol. 7, pp. 629-634, 2016. DOI |
11 | M. Clark, R. D. Cramer III, and N. V. Opdenbosch, "Validation of the General Purpose Tripos 5.2 Force Field", J. Comput. Chem., Vol. 10, pp. 982-1012, 1989. DOI |
12 | R. Kumar, B. Langstrom, and T. Darreh-Shori, "Novel ligands of Choline Acetyltransferase designed by in silico molecular docking, hologram QSAR and lead optimization", Sci. Rep., Vol. 6, p. 31247, 2016. DOI |
13 | A. Balupuri, P. K. Balasubramanian, and S. J. Cho, "A CoMFA study of glycogen synthase kinase 3 inhibitors", J. Chosun Natural Sci., Vol. 8, pp. 40-47, 2015. DOI |
14 | A. Balupuri, P. K. Balasubramanian, and S. J. Cho, "A CoMFA study of quinazoline-based anticancer agents", J. Chosun Natural Sci., Vol. 8, pp. 214-220, 2015. DOI |
15 | A. Balupuri, P. K. Balasubramanian, and S. J. Cho, "Comparative molecular field analysis of pyrrolopyrimidinesas LRRK2 kinase inhibitors", J. Chosun Natural Sci., Vol. 9, pp. 1-9, 2016. DOI |
16 | P. K. Balasubramanian, A. Balupuri, and S. J. Cho, "A CoMFA study of phenoxypyridine-based JNK3 inhibitors using various partial charge schemes", J. Chosun Natural Sci., Vol. 7, pp. 45-49, 2014. DOI |
17 | M. Touat, E. Ileana, S. Postel-Vinay, F. Andre, and J. C. Soria, "Targeting FGFR signaling in cancer", Clin. Cancer Res., Vol. 21, pp. 2684-2694, 2015. DOI |
18 | A. D. Luca, D. Frezzetti, M. Gallo, and N. Normanno, "FGFR-targeted therapeutics for the treatment of breast cancer", Expert Opin. Investig. Drugs, Vol. 26, pp. 303-311, 2017. DOI |
19 | I. S. Babina and N. C. Turner, "Advances and challenges in targeting FGFR signalling in cancer", Nat. Rev. Cancer, Vol. 17, pp. 318-332, 2017. DOI |
20 | K. H. Tiong, L. Y. Mah, and C.-O. Leong, "Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers", Apoptosis, Vol. 18, pp. 1447-1468, 2013. DOI |
21 | E. M. Haugsten, A. Wiedlocha, S. Olsnes, and J. Wesche, "Roles of fibroblast growth factor receptors in carcinogenesis", Mol. Cancer Res., Vol. 8, pp. 1439-1452, 2010. DOI |
22 | H. Greulich and P. M. Pollock, "Targeting mutant fibroblast growth factor receptors in cancer", Trends Mol. Med., Vol. 17, pp. 283-292, 2013. |
23 | H. K. Ho, A. H. Yeo, T. S. Kang, and B. T. Chua, "Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations", Drug Discov. Today, Vol. 9, pp. 51-62, 2014. |